Bringing in the Research Dollars! (BiRD)

Presented by:
The Emory+Children’s Pediatric Research Center

The monthly BiRD announcement highlights pediatric research funding opportunities

Contact stacy.heilman@emory.edu with questions on the funding opportunities highlighted below or for general research grant application advice

April BiRD Highlights

- **NIGMS** sponsored initiative to sponsor collaborative studies examining macromolecular interactions in cells and **NIAID** phased innovation award supporting basic/early-translational research towards development of novel intervention strategies to clear persistent, chronic or latent infectious agents from the host.
- Opportunities to validate candidate disease biomarkers in a variety of well-defined human diseases.
- Foundation funding for clinical research projects directly related to Cystic Fibrosis treatment and care.
- Administrative Supplement available on currently funded NIH awards to support highly innovative research examining ways to modify behavioral/social interventions to improve use in target settings and **NINR** supported opportunity to support interdisciplinary biobehavioral nursing research capacity in Symptom Science Research.
- NIH opportunity to fund research towards elucidating the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism spectrum disorders and funding available from Autism Speaks to fund highly novel and transformative projects.
- CDC funded opportunity to characterize consequences of TBI in children and NIH R01 for research geared towards improving care delivery of emergency medical services for children.
- Funding of projects focused on the nutrition care and development of infants and young children and support for clinical/translational pediatric research that is clinically applicable to the prevention, diagnosis or treatment of pediatric medical problems.
- Support for post hoc activities to do secondary analysis on existing data sets relevant to nutrition, diabetes, endocrine, metabolic and digestive diseases and to perform ancillary studies on acute kidney injury and chronic kidney disease.
- **Exploratory/developmental studies** towards discovering new therapies or means of health promotion and prevention of digestive and liver diseases and nutritional disorders associated with digestive and liver diseases and NIH funds to support the development of new research activities in all areas of cancer research as well as foundation funds directed towards discovering new approaches for cancer treatment.
GA Tech and Pediatrics collaborative opportunities to test the utility and implementation of technological tools towards promoting engagement in HIV care, towards addressing gaps in health care providers’ information needs & the health care decision making processes, an RO1 opportunity to apply nanotechnology approaches to address problems in medicine and seed funds for addressing healthcare needs through engineering approaches and invention.

Global Health research funding from the Bill & Melinda Gates Foundation

AHRQ funding available for support of resources towards improving health outcomes research and award funding for career enhancement of mid and senior investigators interested in patient centered outcomes research

More Career Development opportunities for basic or clinical researchers in the area of inflammatory bowel disease and for scientists involved in a variety of disciplines who study significant biological problems.

Internal pediatric specific pilot research funding opportunities for projects involving collaborations with Yerkes, for community and Children’s employed physicians and for nursing and allied health research.

Pilot funds for researchers based at Grady locations and for research to further knowledge in the area of neonatal resuscitation.

Diabetes related grants available for research related to islet cell transplantation, macrovascular disease & neuropathy as well as towards funding alternative, complementary, integrative, and nutritional therapies to prevent, treat, and cure diabetes and its complications.

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Collaborations for Macromolecular Interactions in Cells (R01)</th>
</tr>
</thead>
</table>

**Purpose**

To establish inter-disciplinary collaborative projects to advance studies of macromolecular interactions and their relationship to function in cells. These collaborations are designed to integrate additional research strategies into NIGMS' research base of laboratories specializing in macromolecular function in living systems. Grantees may use this funding opportunity to (i) complement each other's capabilities (for example, in biochemistry, genetics, chemistry, or pharmacology), where the innovation is in the biology rather than in the technology; (ii) apply proven technologies that are technically challenging, expensive, or not yet widely used in cell biology and allied fields (for example, mass spectrometry, high-throughput screening); (iii) develop, pilot, evaluate, and/or apply emerging technologies (for example, superresolution light microscopy); (iv) carry out feasibility studies or upstream research and development of new technological concepts that are unproven, but potentially useful for study of macromolecular interactions. This FOA invites unconventional research strategies, including exploratory, descriptive, and statistical approaches, and encourages discovery and hypothesis generation as research objectives.

**Funds Avail**

The maximum award budget is $250,000/year direct costs for a maximum of 4 years.

**Deadline**

June 14, 2012

**Remarks**

- This FOA is intended to accommodate unconventional research
objectives and approaches that fall outside the traditional hypothesis-driven framework that is often favored in peer review

- This FOA uses the NIH multiple program director(s)/principal investigator(s) (PD(s)/PI(s)) grant, the R01 activity, and the modular budget grant application format.
- A priority of this FOA is to support collaborations in which (i) at least half of the PD(s)/PI(s) are modestly funded NIGMS grantees (total support to the laboratory under $400,000/year direct costs) and (ii) at least half of the PD(s)/PI(s) are PD(s)/PI(s) of an NIGMS research grant with a primary specialization in molecular systems and mechanisms in live organelles, cells, tissues or organisms that is active or has been active within the last four years.

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Use-Oriented Basic Research: Change Mechanisms of Behavioral Social Interventions (Admin Supp)</th>
</tr>
</thead>
</table>

**Purpose**

This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact. This announcement was developed by a Common Fund program called the Science of Behavior Change (SOBC) (http://commonfund.nih.gov/behaviorchange/). The SOBC program seeks to promote research across disciplines on the initiation, personalization, and maintenance of behavior change that leads to an improved understanding of the underlying principles of behavior change. Like all Common Fund initiatives, this SOBC initiative invites investigators to develop bold, innovative, and potentially risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress. One seemingly intractable problem is the gap between practice and research, in which treatments shown to be efficacious under controlled conditions are not adopted for use, or are unsustainable, in practice settings. There is debate in the behavioral and social sciences fields about how best to bridge this gap, with some investigators focusing on modifying the intervention, and others focusing on modifying the delivery system. This announcement focuses on the former. It acknowledges that there are multiple pathways to bridging the practice-research gap, but focuses on a pathway consistent with the mission of the SOBC program. Specifically, this FOA solicits administrative supplement applications to study possible mechanisms of action of behavioral or social interventions, with the ultimate aim of informing the simplification or other modifications of behavioral or social interventions to improve use in target settings and by target interventionist

**Funds Avail**

Supplement requests for up to $75,000 direct costs will be accepted. Intended to provide 1 year of support, but requests for 2 years will be considered with compelling justification.

**Deadline**

May 15, 2012

**Remarks**

- Additional funds may be awarded as supplements to parent awards using the following Activity Code(s): P01, P20, P30, P50, U54, R00, R01, R15, R21, R33, R34, R37, U01
- Only one application per parent award is allowed.
<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Research on Autism and Autism Spectrum Disorders (R01)</th>
</tr>
</thead>
</table>

**Purpose**

Encourages research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism spectrum disorders (ASD). Basic, clinical, and applied studies are encouraged. This FOA is intended to support the broad research goals of the Strategic Plan for ASD Research (http://iacc.hhs.gov/reports/2009/iacc-strategic-plan-for-autism-spectrum-disorder-research-jan26.shtml).

**Funds Avail**

The total project period for an application submitted in response to this FOA may not exceed 5 years. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.

**Deadline**

Standard NIH Due Dates*

**Remarks**

- Companion FOA’s include:
  - Small Research Grant (R03) award mechanism

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Characterizing the Short and Long Term Consequences of Traumatic Brain Injury (TBI) among Children in the United States</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://www.grants.gov/search/search.do?mode=VIEW&amp;oppId=147334">http://www.grants.gov/search/search.do?mode=VIEW&amp;oppId=147334</a></td>
<td></td>
</tr>
</tbody>
</table>

**Purpose**

Sponsored by the CDC National Center for Injury Prevention and Control (NCIPC), this funding announcement is soliciting research that will help expand and advance the understanding of how traumatic brain injury (TBI) impacts the developmental milestones of children. To address these issues, this announcement solicits research to achieve these research objectives:

- Characterize the TBI injury received in terms of age at injury, external cause of injury, severity of injury, anatomical location of injury, and type of injury.
- Describe the natural history of TBI post-injury and treatment(s) received during the acute, post-acute/short-term, and longer-term phases. This should include at least information about signs and symptoms, complications, characteristics of treatment (such as rapidity, type, and facility level), neurological and functional status, discharge disposition, and other consequences arising from TBI.
- Describe the short-term and long-term consequences of TBI post-injury, such as school performance, economic impact, behavioral problems, impact on the family system, and need for supportive services.
- Characterize the similarities and differences in the attainment of developmental milestones for children who survived a TBI in each of the standard developmental stages.

**Funds Avail**

The maximum award amount will be $550,000 total direct and indirect costs for the first 12-month budget period. Project period length is 5 years.

**Deadline**

May 2, 2012
Remarks

- Expected number of awards: 2

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Secondary Analysis in Obesity, Diabetes and Digestive and Kidney Diseases (R21)</th>
</tr>
</thead>
</table>

**Purpose**

This Funding Opportunity Announcement (FOA), encourages R21 applications that propose to conduct secondary analysis of existing data sets relevant to diabetes and endocrine and metabolic diseases; digestive diseases and nutrition, including obesity and eating disorders; and kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets.

Applicants may conduct secondary analyses using data from a variety of sources. These would include investigator-initiated research activities, cooperative agreements, and contracts or from other public or private sources. Applicants may also secure access to other data sets that may or may not be in the public domain, such as those collected under research grant funds, sponsored by private entities, or originally collected for purposes other than research, such as health care administrative datasets.

**Funds Avail**

Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

**Deadline**

Standard NIH Due Dates*

**Remarks**

- This FOA issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the Office of Dietary Supplements (ODS)
- Major interests of NIDDK in supporting secondary data analyses are restricted to those on which NIDDK conducts research, which include diabetes and endocrine and metabolic diseases; digestive diseases and nutritional disorders, including eating disorders; and kidney, urological, and hematological diseases.
- This funding opportunity addresses several areas considered to be high priority for liver disease research as delineated in the recently published Trans-NIH Action Plan for Liver Disease Research (http://liverplan.niddk.nih.gov), specifically in the areas of fatty liver disease, viral hepatitis, drug- and toxicant-induced liver disease, autoimmune liver disease, pediatric liver disease, liver transplantation, complications of liver disease, and gallbladder and biliary disease.
- The Office of Dietary Supplements (ODS) encourages new exploratory and developmental research projects through secondary data analyses that are focused on evaluating dietary supplement intake to estimate prevalence, frequency, duration, and type of use with the underlying goal of determining the relationship of usage patterns to health and disease risks.

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Ancillary Studies of Acute Kidney Injury, Chronic Kidney Disease, and End Stage Renal Disease Accessing Information from Clinical Trials, Epidemiological Studies, and Databases (R01)</th>
</tr>
</thead>
</table>
**Purpose**

Inviting investigator-initiated research project applications for ancillary studies to ongoing or completed clinical trials, existing administrative and clinical databases and epidemiological studies of kidney disease as well as clinical trials and epidemiological studies for other diseases or populations that lend themselves to the study of acute kidney injury and chronic kidney disease. These studies may range from new analyses of existing datasets of completed studies to additional collection of data and biological specimens in ongoing investigations. The goal of these studies should be to extend our understanding of the risk factors for developing kidney disease and their associated co-morbid illnesses such as malnutrition and cardiovascular disease, factors associated with rapid decline in kidney function among persons with chronic kidney disease, and the impact of these diseases on quality of life and mental and physical functioning. Investigations of acute kidney injury, including biomarkers is also an appropriate topic for investigation. Studies ancillary to both government and non-government supported clinical trials and epidemiological studies are encouraged. Analysis of large public access databases and other databases is also encouraged.

**Funds Avail**

Budget is not limited in dollars but needs to reflect the actual needs of the proposed projects. Maximum project period is 5 years.

**Deadline**

Standard NIH Due Dates*

**Remarks**

- Please note that this particular RFA expires in Sept of this year so if it is not to be renewed, the only remaining deadline is June 5, 2012

---

**Program/Link**

Pilot and Feasibility Clinical Research Studies in Digestive Diseases and Nutrition (R21)


**Purpose**

Encourages pilot and feasibility clinical and epidemiological research studies of new therapies or means of health promotion and prevention of digestive and liver diseases and nutritional disorders associated with digestive and liver diseases. Examples of the rare or uncommon digestive and liver diseases that are of particular focus in this funding opportunity include gastrointestinal motility disorders of children; eosinophilic gastroenteritis, intestinal pseudoobstruction, Wilsons disease; sclerosing cholangitis in children; hepatic congenital fibrosis; autoimmune hepatitis; primary biliary cirrhosis; and familial pancreatitis.

**Funds Avail**

Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. Total project period may not exceed 2 years.

**Deadline**

Standard NIH Due Dates*

**Remarks**

- Issued by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) & the National Cancer Institute, and the Office of Dietary Supplements (ODS)

---

**Program/Link**

Research on Emergency Medical Services for Children (EMSC) [R01]


**Purpose**

This Funding Opportunity Announcement (FOA) is designed to improve the quality and quantity of research related to emergency medical services for
children (EMSC), with the goal of reducing morbidity and mortality in children through improved care delivery. This FOA invites the submission of applications dealing with the following areas of research included under the term EMSC: prevention research to reduce the need for emergency care; clinical research to ensure that children receive high-quality and appropriate medical, nursing and mental health care in an emergency; health systems research, from pre-hospital care, to the emergency department, to in-patient care and return to the community; models to improve service and cost efficiency in pediatric emergency care; and methodological studies to improve the quality of research conducted.

**Funds Avail**  
Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum period is 5 years.

**Deadline**  
Standard NIH Due Dates*

**Remarks**  
- Companion FOA Exploratory/Developmental R21 Grant  

| Program/Link | Centers of Excellence in Symptom Science: Building Research Teams for the Future (P20)  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose</strong></td>
<td>The National Institute of Nursing Research (NINR) invites applications to establish Centers of Excellence for Symptom Science: Building Research Teams for the Future (P20). This FOA supports applications to develop interdisciplinary biobehavioral nursing research capacity in Symptom Science Research.</td>
</tr>
<tr>
<td><strong>Funds Avail</strong></td>
<td>It is anticipated that support will be provided for up to 2-3 new P20 Centers for Building the Research Teams of the Future. Support may be requested for up to 5 years, not to exceed $300,000 total costs (direct plus F&amp;A costs) per year. The maximum period is 5 years.</td>
</tr>
</tbody>
</table>
| **Deadline**  | May 16, 2012  
  Institutions may only submit one application in response to these FOA’s (both the P20 and P30). To seek approval for submission through Emory University, the deadline is April 9, 2012** |
| **Remarks**  |  
  - This call for Center applications focuses on  
    - Pain  
    - Sleep Disturbances  
    - Fatigue  
    - Cognitive/affect changes  
  - Interested applicants based at Emory should email Holly Sommers (hsomme2@emory.edu) an abstract and NIH biosketch no later than 4/9/12  
  - Companion FOA – Center Core P30 Grant  

| Program/Link | Technology-Based Interventions to Promote Engagement in Care and Treatment Adherence for Substance Abusing Populations with HIV (R01)  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose</strong></td>
<td>Encourages Research Project Grant (R01) applications to test the utility and</td>
</tr>
</tbody>
</table>
implementation of technological tools, including mobile devices, to promote engagement in Human Immunodeficiency Virus (HIV) care among substance abusing populations with HIV. Research projects may focus on (a) the use of technology to directly improve patient-level outcomes (i.e., adherence); (b) the capacity of HIV treatment providers and related service delivery organizations to adopt and integrate such technologies to promote HIV treatment outcomes; or (c) the use of technology to improve the organization and delivery of HIV treatment and services.

**Funds Avail**  
Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum period is 5 years.

**Deadline**  
Standard NIH Due Dates*

**Remarks**  
- Companion FOA Clinical Trial Planning R34 Grant Program  
- Issued by National Institute on Drug Abuse (NIDA)
- This research should occur in community and clinic-based settings

**This funding opportunity has strong collaborative potential between groups at GA Tech and physicians at Children’s Healthcare of Atlanta**

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Partnerships for Interventions to Treat Chronic, Persistent and Latent Infections (R21/R33)</th>
</tr>
</thead>
</table>

**Purpose**  
Seeks to stimulate basic and early-stage translational research focused on development of novel intervention strategies to clear persistent, chronic or latent infectious agents from the host. Responsive applications will define and address a therapeutic need specific to a targeted pathogen and must address discovery and/or development of new interventions against one or more agents where the clinical relevance of persistent, chronic and/or latent infection, or reactivation there from, in immune-competent hosts is well-established in the scientific literature.

**Funds Avail**  
Support for the R21 phase cannot exceed two years and total direct costs are limited to $275,000 over the R21 two-year period, with a maximum of $200,000 in direct costs allowed in any single year. The R33 award phase is limited to $300,000 in direct costs per year and cannot exceed three years.

**Deadline**  
July 13, 2012

**Remarks**  
- R21/R33 is a Phased Innovation Award
- NIAID anticipates that a maximum of fifty percent (50%) of the funded R21 phase awards will progress to the R33 award.

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Nanoscience and Nanotechnology in Biology and Medicine (R01)</th>
</tr>
</thead>
</table>

**Purpose**  
Encourages applications from institutions/organizations that apply nanoscience and nanotechnology approaches to address problems in biology and medicine. The purpose of this FOA is to provide support for cutting-edge nanoscience and nanotechnology research that can lead to biomedical breakthroughs and new investigations into the diagnosis, treatment and management of an array of diseases and traumatic injuries. Nanoscience and
nanotechnology have the capacity to drive a new wave of medical innovation through the engineering of bioactive nanoscale structures, processes and systems based on the advancement of our understanding of biology at the nanoscale. Therefore, this FOA will also support research projects that develop new or improved nanotechnology and nanoscience-based tools, methods, concepts, and devices that lead to a better understanding of basic biology in addition to conducting translational biomedical studies.

**Funds Avail**  
Application budgets are not limited, but need to reflect actual needs of the proposed project. Project period maximum is 5 years.

**Deadline**  
Standard NIH Due Dates*

**Remarks**
- See RFA for identified areas of interest of participating I/C’s including but not limited to NICHD, NCI, NHLBI, NIAID, NIAMS and NINR

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Infrastructure Development Program in Patient-Centered Outcomes Research (PCOR) (R24)</th>
</tr>
</thead>
</table>

**Purpose**  
Soliciting Resource-Related Research Projects (R24) grant applications from organizations that propose to improve health outcomes by developing and disseminating evidence-based information to patients, clinicians, policy makers, and health care administrators, responding to their expressed needs about which clinical and health system design interventions are most effective for which patients under specific circumstances.

**Funds Avail**  
A budget of up to $1 million per year in total annual costs and a time period of up to five years may be requested.

**Deadline**  

**Remarks**
- Issued by AHRQ
- A minimum time commitment of 1.8 calendar months (i.e. 15%) annual effort is required from the PD/PI
- Multiple PI applications are not permitted
- R24’s are Resource-Related Research Projects and are meant to support research projects that will enhance the capability of resources to serve biomedical research

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Understanding Clinical Information Needs and Health Care Decision Making Processes in the Context of Health Information Technology (IT) (R01)</th>
</tr>
</thead>
</table>

**Purpose**  
To fund research aimed at elucidating the nature of cognition, task distribution, and clinical work in various health care delivery settings. Research projects funded under this FOA will address current knowledge gaps regarding our understanding of health care providers’ information needs and health care decision making processes, both individually and collectively, and as a health care team (composed of doctors, nurses, therapists, and administrative staff).

**Research Areas of Interest.** This FOA is focused on four areas of interest:

1. The nature of clinical work in context;
2. The nature of clinical expertise in individual and team decision making;
3. The nature of data visualization to support skill-based, rule-based, and knowledge-based cognitive control for the health care team; and
4. Understanding how the health care team manages missing data or data of questionable validity or accuracy when making health care decisions.

**Funds Avail**
The total costs for a grant awarded under this FOA will not exceed $500,000 per year for a project period of up to five (5) years.

**Deadline**
Standard NIH Due Dates*

**Remarks**
- Issued by AHRQ
- See RFA for special application page limitations
- Research proposals should draw from many fields and domains such as system sciences (e.g., operations research including stochastic and deterministic approaches, workflow modeling, system dynamics, quality engineering, and human factors engineering) and sociotechnical systems research. Other fields that have the potential to contribute include cognitive psychology and decision science.

**This funding opportunity has strong collaborative potential between groups at GA Tech and physicians at Children’s Healthcare of Atlanta**

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Development and Validation of Disease Biomarkers (R01)</th>
<th><a href="http://grants.nih.gov/grants/guide/pa-files/PA-09-204.html">http://grants.nih.gov/grants/guide/pa-files/PA-09-204.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose</strong></td>
<td>To validate candidate biomarkers for well-defined human diseases of the liver, kidney, urological tract, and digestive and hematologic systems, as well as endocrine and metabolic disorders, diabetes and its complications, and obesity, for which there are no or very few biomarkers, or for. Appropriate studies will validate candidate biomarkers in well-defined patient populations, provide new technologies to monitor biomarkers or establish reliable assays for validated markers. Progress in this area has the potential to advance translational research related to efficacy of treatments and bio-behavioral interventions. This FOA is not appropriate for biomarker discovery projects.</td>
<td></td>
</tr>
<tr>
<td><strong>Funds Avail</strong></td>
<td>Budget is not limited in dollars but needs to reflect the actual needs of the proposed projects. Maximum project period is 5 years.</td>
<td></td>
</tr>
<tr>
<td><strong>Deadline</strong></td>
<td>Standard NIH Due Dates*</td>
<td></td>
</tr>
<tr>
<td><strong>Remarks</strong></td>
<td>Please note that this particular RFA expires in Sept of this year so if it is not to be renewed, the only remaining deadline is June 5, 2012</td>
<td></td>
</tr>
</tbody>
</table>

An application submitted in response to this funding opportunity could benefit from the involvement of the Pediatric Biomarkers Core. Please contact stacy.heilman@emory.edu for more information.

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)</th>
<th><a href="http://grants.nih.gov/grants/guide/pa-files/PAR-12-145.html">http://grants.nih.gov/grants/guide/pa-files/PAR-12-145.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose</strong></td>
<td>The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in all areas of cancer research. The R21 mechanism is intended to</td>
<td></td>
</tr>
</tbody>
</table>
encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).

**Funds Avail**
The combined budget for direct costs for the 2-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined 2-year award period.

**Deadline**
Standard NIH Due Dates*

**Remarks**
- Companion FOA – Small Grant R03 Program

## FOUNDATION

### Elsa U. Pardee Foundation

**Program/Link**
[http://www.pardeefoundation.org/index.htm](http://www.pardeefoundation.org/index.htm)

**Purpose**
Grants support research programs directed toward discovering new approaches for cancer treatment and cure and financial support for cancer treatment.

**Funds Avail**
In 2010 the Foundation gave $3,016,754 for 21 grants (high: $400,000; low: $7,200).

**Deadline**
Rolling

**Remarks**
- The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers.
- It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding.

### Autism Speaks Suzanne and Bob Wright Trailblazer Award

**Program/Link**

**Purpose**
Autism Speaks places a high priority on innovation and has designed its new Trailblazer Award to respond quickly to fund highly novel transformative projects. The Trailblazer Award mechanism will support highly novel “out of the box” autism-relevant research that opens new avenues to understanding the causes, diagnosis, subtyping, prevention, treatments, and cure of autism spectrum disorders. The Trailblazer Award mechanism is designed to fund small investigator-initiated high risk/high impact projects that are potentially transformative, paradigm shifting, and/or will overcome significant roadblocks in autism research within a 12 month period.

**Funds Avail**
$100,000 for 1 year max

**Deadline**
LOI’s Accepted on a Rolling Basis. Those that are deemed exceptional in meeting the screening criteria will be invited to submit a full application.

**Remarks**
- Applications must explore a highly novel idea or research technique that potentially could have high impact, i.e., have the capacity to change the
way we diagnose, subtype, prevent, and/or treat ASD or the way we conduct relevant research on ASD.

- Applications generally should not have preliminary data.
- Applications should be considered so risky as to not likely be supported though other AS grants programs, including pilot studies.
- Eligibility Requirements: Investigators should hold a full-time tenured or tenure-track faculty appointments or equivalent full time non-tenure track appointments at accredited academic, medical or research institutions

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Cystic Fibrosis Foundation (CFF) Clinical Research Awards</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose</strong></td>
<td>These awards offer support to clinical research projects directly related to Cystic Fibrosis (CF) treatment and care. Projects may address diagnostic or therapeutic methods related to CF or the pathophysiology of CF.</td>
</tr>
<tr>
<td><strong>Funds Avail</strong></td>
<td>Up to $100,000 per year for up to three years may be requested for single-center clinical research grants. For multi-center clinical research, the potential award is up to $225,000 per year for up to three years.</td>
</tr>
<tr>
<td><strong>Deadline</strong></td>
<td>Letter of Intent: June 1, 2012, by 5pm</td>
</tr>
<tr>
<td><strong>Remarks</strong></td>
<td>Applicants must demonstrate access to a sufficient number of CF patients from accredited CF Foundation care centers and appropriate controls.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>The Gerber Foundation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose</strong></td>
<td>The Gerber Foundation’s mission focuses on the nutrition, care and development of infants and young children. Therefore, grant-making interests are focused on health and/or nutrition-related research having a significant impact on issues facing infants and young children from the first year before birth to age 3. The Foundation is particularly interested in fresh approaches to solving newborn or pediatric problems or emerging issues with a predictable time frame to clinical application. Projects should be focused on issues faced by care providers that, when implemented, will improve the health, nutrition and/or developmental outcomes for infants and young children. Projects may include:</td>
</tr>
<tr>
<td><strong>Funds Avail</strong></td>
<td>Awards and time periods vary depending upon the specific project. Research</td>
</tr>
</tbody>
</table>
projects may be no longer than 3 years in length. Total grant size should be no more than roughly $300,000.

**Deadline**

For the November Grant Round:
- Concept papers: Due June 1, 2012
- Upon invitation, full proposals: Due Aug 15, 2012

**Remarks**

➤ Foundation grants are not typically ongoing. Supported projects should have beginnings and endings, reasonable periods during which measurable progress or outcomes are accomplished.

➤ Determination of interest in receiving a full proposal will be made by end of May

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Thrasher Research Fund</th>
</tr>
</thead>
</table>

**Purpose**

The Thrasher Research Fund remains open to a variety of pediatric medical research topics. Research projects with the potential to impact a large number of children as well as research projects that address severe problems affecting relatively few children will be considered. The fund seeks to maintain a portfolio of grants with a balance of both domestic and international research.

The fund supports clinical/translational pediatric research. Emphasis is placed on projects with potential findings that would be clinically applicable in a relatively short period of time for the prevention, diagnosis or treatment of pediatric medical problems.

**Funds Avail**

Projects are supported for up to three years. The grant amount is based on the actual budgetary needs of the project. In 2009-2010 the median grant was $300,000 for the total award (not annually).

**Deadline**

➤ No set deadline: Concept papers (see website for template) are accepted on a rolling basis, and are considered by the Fund’s Executive Committee approximately once per month.

➤ The Fund awards grants three times per year, with no fixed number of awards given in each funding cycle or in each year.

➤ If a full proposal is invited, the applicant will have one year to submit a full proposal. Full proposals recommended by peer reviewers for further consideration are considered by the Fund’s Committees in February, June, or October.

**Remarks**

➤ There are no citizenship or residency requirements.

➤ Investigator salary support may not exceed 20%

➤ Thrasher also offers a mentored Early Career Award that awards up to $25K. Eligible individuals include physicians who are in a residency/fellowship training program, or who completed that program no more than one year before the date of submission of the concept paper. Post-doctoral researchers who received the doctoral level degree no more than three years prior to the date of submission of the concept paper may also apply. **The next deadline for submitting a concept paper for consideration under this Early Career Award award is June 15, 2012, at noon Mountain Time.** The final concept paper
Purpose
Each round of the Grand Challenges Explorations initiative awards grants against a set of specific topics. In general, topics are chosen according to three major criteria:

- The topic fits within the goals and disease priorities of the Bill & Melinda Gates Foundation
- The topic contains a roadblock where radical, new thinking is needed for the discovery of an effective health solution
- Potential projects within the topic are likely to be well suited for the phased structure of the initiative

Consideration is given as to whether a topic will engage the participation from scientists outside traditional global health disciplines, as well as researchers working in the developing world.

Topics for Grand Challenges Explorations Round 9 are:

- New Approaches for the Interrogation of Anti-malarial Compounds - new!
- Aid is Working. Tell the World - new!
- Explore New Solutions for Global Health Priority Areas
- Design New Approaches to Optimize Immunization Systems
- Protect Crop Plants from Biotic Stresses From Field to Market

Funds Avail
Phase I grants will be for $100,000 USD. Phase I projects that show promise in the first year will be eligible for follow-on funding.

Deadline
Proposals due Tuesday, May 15, 2012, 11:30 a.m. U.S. Pacific Daylight Time

Remarks
- Citizenship is Unrestricted
- The grant program is open to anyone from any discipline, from student to tenured professor, and from any organization - colleges and universities, government laboratories, research institutions, non-profit organizations and for-profit companies.
- They anticipate funding approximately sixty awards each round. Promising first-year projects will be eligible for additional follow-on funding.

CAREER DEVELOPMENT/TRAINING

Program/Link
AHRQ Mentored Career Enhancement Award in Patient Centered Outcomes Research (PCOR) for Mid-Career and Senior Investigators (K18)

Purpose
This Funding Opportunity Announcement (FOA) issued by AHRQ, invites applications for Mentored Career Enhancement grant awards (K18) in
Patient Centered Outcomes Research (PCOR). The program targets established mid-career and senior investigators who are interested in developing new skills in comparative effectiveness research methodology and applying these methods to patient-centered outcome research (PCOR).

**Funds Avail**
Budget proposals must not exceed $275,000 total costs annually. Total project period should be between 6-24 months.

**Deadline**

**Remarks**
- Candidates must hold the rank of Associate Professor or Professor, or their equivalent in non-academic settings
- Candidates must commit a minimum of 6 full-time calendar months (equivalent to 50% of full-time professional effort) to their career enhancement in PCOR across a period ranging from six months to two years
- The career development experience must involve an intense, mentored career development plan in comparative effectiveness research, which will substantially improve the candidate’s ability to pursue future research in PCOR.

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Howard Hughes Medical Institute (HHMI) Investigator Competition <a href="http://www.hhmi.org/research/competitions/">http://www.hhmi.org/research/competitions/</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose</strong></td>
<td>This HHMI investigator competition is open to scientists at more than 200 eligible institutions who study significant biological problems in all of the biomedical disciplines, as well as in adjacent fields such as biophysics, chemical biology, biomedical engineering, and computational biology. Plant scientists, experimental evolutionary biologists, and patient-oriented researchers are welcome to apply. Those selected in this competition will receive a five-year appointment to HHMI, which is renewable pending favorable scientific review.</td>
</tr>
<tr>
<td><strong>Funds Avail</strong></td>
<td>Budget not submitted with application; If awarded HHMI will pay full salary and benefit to awardee, some staff and provides some staff and research operational funds</td>
</tr>
</tbody>
</table>
| **Deadline** | Deadline to establish eligibility: May 1, 2012  
Deadline to submit application: June 13, 2012 |
| **Remarks** | Successful candidates are expected to meet the following criteria:  
- Hold a Ph.D., and/or M.D. or equivalent degree.  
- Hold a tenured or tenure-track position as Assistant Professor or higher academic rank (or the equivalent) at an eligible institution.  
- Have more than 5 but no more than 15 years of experience since appointment as an assistant professor or equivalent position.  
- Be the principal investigator on one (or more) active, national, peer-reviewed research grants with a duration of at least three years.  
- Required to devote 75% total effort to direct conduct of biomedical research |

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Crohn’s &amp; Colitis Foundation of America Career Development Award <a href="http://www.ccfa.org/ccfaprof/cda/index.html">http://www.ccfa.org/ccfaprof/cda/index.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose</strong></td>
<td>To encourage the development of individuals with research potential to help</td>
</tr>
</tbody>
</table>
them prepare for an career of independent basic and/or clinical investigation in the area of inflammatory bowel disease. Therefore, individuals who are already well established in the field of IBD research are not considered eligible for this award.

**Funds Avail**  
Up to $90,000 per year for 1-3 years  
**Deadline**  
Letter of Intent: May 1, 2012  
Upon invitation only - Full application deadline: July 1, 2012  
**Remarks**  
- Candidates holding MD degrees must have five years of post doctoral experience, two years of which must be documented research experience relevant to IBD. Generally, the candidates must not be in excess of ten years beyond the attainments of the doctoral degree. Applicants holding PhDs must have at least two years of documented post-doctoral research relevant to IBD.  
- The awardee must devote a minimum of 80% of his/her time directly to the project  
- CCFA also offers a Research Fellowship award where 90% research effort is required: [http://www.ccfa.org/ccfaprof/rfa/index.html](http://www.ccfa.org/ccfaprof/rfa/index.html)

### INTRAMURAL/SEED/PILOT

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Pediatric/Yerkes Pilot Research Projects – Call for Letters of Intent</th>
</tr>
</thead>
</table>

**Purpose**  
A partnership between Emory+Children’s Pediatric Research Center & Yerkes National Primate Research Center announces this request for Letters of Intent (LOI) for pilot projects that will lead to collaborative pediatric research and significant extramural funding. Research project ideas addressing an area of child health research utilizing a model of non human primates or rodents are sought.

**Funds Avail**  
It is expected that two $30K one year awards will be made.

**Deadline**  
April 16, 2012

**Remarks**  
- In no more than one page, the LOI should provide the following:  
  1. Project Title  
  2. Brief description of the proposed pilot project for which the pilot funds would be used  
  3. Alignment with the missions of the Emory+Children’s Pediatric Research Center & Yerkes National Primate Research Center  
  4. Intended subsequent extramural grant application type, agency, and deadline for submission (must be submitted within one year of the conclusion of funding of this pilot award)  
- Letters should be submitted to [barbara.kilbourne@choa.org](mailto:barbara.kilbourne@choa.org) by April 16, 2012, at 5pm

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Friends Research Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>For community and Children's employed physicians <a href="http://www.choa.org/Health-Professionals/Clinical-Research/Funding-Opportunities">http://www.choa.org/Health-Professionals/Clinical-Research/Funding-Opportunities</a></td>
</tr>
</tbody>
</table>

**Purpose**  
A unique research initiative funding Children’s physicians' clinical research
projects that translate directly to the improvement of quality care to Children's patients. Administered by the Clinical Research Oversight Committee (CROC), the Friends Research Fund supports competitive grants bi-annually. These grants are for well-defined research projects, pilot studies and seed grants that typically last 6 to 18 months.

**Funds Avail** $50,000 for awards lasting 6-18 months.

**Deadline** May 4, 2012

**Remarks**
- Applications are open to all members of the Children’s professional staff that provide services on site in one of the Children’s facilities.
- Only clinical research projects will be considered
- Please contact Kris Rogers, Director of Clinical Research, at kris_rogers@cha.org with questions

### Program/Link

**Dudley L. Moore Nursing & Allied Health Research Fund**  
For nurses and allied health professionals  
[http://www.cha.org/Health-Professionals/Clinical-Research/Funding-Opportunities](http://www.cha.org/Health-Professionals/Clinical-Research/Funding-Opportunities)

**Purpose**  
The Dudley Moore Fund provides grant funding for research proposals which will have an impact on enhanced patient care. Accordingly, priority is given to proposals which have the capacity to change practice based on evidence and upon evaluation change will be evident.

**Funds Avail**  
The maximum amount of funding available per project is $15,000

**Deadline** May 4, 2012

**Remarks**
- The Dudley Moore Fund provides grant funding for research proposals which will have an impact on enhanced patient care. Accordingly, priority is given to proposals which have the capacity to change practice based on evidence and upon evaluation change will be evident.
- Please contact Dr. Linda Riley, Director Nursing Research & Evidence Based Practice, at linda.riley@cha.org with questions

### Program/Link

**TRIBES-GTRI 2012 Translational Seed Grant Opportunity**  

**Purpose**  
The Translational Research Institute for Biomedical Engineering and Science (TRIBES) and the Georgia Tech Research Institute (GTRI) are opening a request for applications (RFA) for a translational research seed grant opportunity with the goals of:

- Fostering collaboration between Georgia Tech and GTRI investigators focusing on healthcare needs.
- Promoting the rapid transfer of new knowledge and inventions based on that knowledge to the commercial sector.
- Translating technologies that are at a basic science/research phase into a prototype, “Coulter-ready” grant proposal.

**Funds Avail**  
Between $25K - $40K for 1 year

**Deadline** April 23, 2012, by 5pm

**Remarks**
- Multiple principle investigators are permitted. Projects that facilitate collaborative partnerships between GT and GTRI, and include a clinical advisor are strongly encouraged.
<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Diabetes Research Wellness Foundation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose</td>
<td>DRWF is offering financial support for a selected number of proposals and projects connected with diabetes research. Applications should be related to finding the cause, prevention, treatment and cure of diabetes and its complications. Currently, the Foundation’s area of primary interest and focus are islet cell transplantation, macrovascular disease &amp; neuropathy. All other research proposals will not be reviewed.</td>
</tr>
<tr>
<td>Funds Avail</td>
<td>$50,000 annually for a maximum of 2 years.</td>
</tr>
<tr>
<td>Deadline</td>
<td>June 30th and Dec 30th of each year</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Diabetes Action Research Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose</td>
<td>Diabetes Action is committed to funding promising and innovative diabetes research with a special interest in alternative, complementary, integrative, and nutritional therapies to prevent, treat, and cure diabetes and its complications. Types of research supported by this foundation includes:</td>
</tr>
<tr>
<td></td>
<td>- Promising and innovative research related to diabetes with a focus on alternative, complementary, and nutritional therapies to prevent and treat diabetes and its complications.</td>
</tr>
<tr>
<td></td>
<td>- Clinical and functional studies for the development and testing of new treatments or interventions to alleviate the consequences of diabetes.</td>
</tr>
<tr>
<td></td>
<td>- Design and development of new or improved rehabilitative or technological devices for individuals with diabetes.</td>
</tr>
<tr>
<td>Funds Avail</td>
<td>$40,000 for 1 year</td>
</tr>
<tr>
<td>Deadline</td>
<td>June 1, 2012</td>
</tr>
<tr>
<td>Remarks</td>
<td>Contact <a href="mailto:stacy.heilman@emory.edu">stacy.heilman@emory.edu</a> if you would like to review the application requirements.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Program/Link</th>
<th>Emory Medical Care Foundation (EMCF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose</td>
<td>Emory Medical Care Foundation grants support the research careers of junior investigators and more senior investigators interested in pursuing research. The grant program is designed to provide financial support for clinical studies that are related to the health care needs of the patients served by Grady or basic science projects that have clinical significance. The small grant program is meant to help individuals collect pilot data to be used for submissions to external grant agencies, as well as to encourage clinicians and educators to engage in clinical and basic science research. Applicants must be Emory faculty and must be based at Grady Memorial Hospital at least 50% of their time.</td>
</tr>
<tr>
<td>Funds Avail</td>
<td>$30,000</td>
</tr>
<tr>
<td>Deadline</td>
<td>June 1, 2012</td>
</tr>
<tr>
<td>Remarks</td>
<td>Funding is limited to faculty based at Grady at least 50% time.</td>
</tr>
</tbody>
</table>
Grants will only be awarded to Emory faculty during their first ten years at Grady. In addition, grants will only be awarded to individuals who completed their specialty, subspecialty, or postdoctoral fellowship training in the prior ten years.

|--------------|------------------------------------------------------------------------------------------|-----------------------------------------------------------------|

**Purpose**
Funds are available from the American Academy of Pediatrics Neonatal Resuscitation Program (NRP) and Section on Perinatal Medicine to support research that furthers knowledge in the area of neonatal resuscitation. These funds may be used to generate pilot data to allow the investigator to develop the basis for an application for independent research support through conventional granting mechanisms. Submitted studies may be basic, clinical, educational or epidemiological research pertaining to the broad area of neonatal resuscitation.

**Funds Avail**
$50,000

**Deadline**
Letter of Intent: May 4, 2012
Application (by invitation only): Aug 17, 2012

**Remarks**
- A **Young Investigator Award** is also offered and is available to residents, fellows-in-training or those professionals who are no more than four years out of their fellowship.

### Other Research Related Announcements

**Request for Information (RFI): Priorities for Outsourcing of Laboratory Procedures**

Seeking input from researchers regarding current research laboratory procedures that could be developed into outsourced services.

All comments must be submitted electronically to: http://public.nigms.nih.gov/sbir/. Please respond by COB May 1, 2012.

### NIH STANDARD DUE DATES CITED ABOVE

<table>
<thead>
<tr>
<th>Mechanism(s)</th>
<th>Cycle I</th>
<th>Cycle II</th>
<th>Cycle III</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Due Date</td>
<td>Due Date</td>
<td>Due Date</td>
</tr>
<tr>
<td><strong>P Series</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL – new, renewal, resubmission, revision</td>
<td>25-Jan</td>
<td>25-May</td>
<td>25-Sept</td>
</tr>
<tr>
<td><strong>R01</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW</td>
<td>5-Feb</td>
<td>5-Jun</td>
<td>5-Oct</td>
</tr>
<tr>
<td>renewal, resubmission, revision</td>
<td>5-Mar</td>
<td>5-Jul</td>
<td>5-Nov</td>
</tr>
<tr>
<td>All - new, renewal, resubmission, revision</td>
<td>5-April</td>
<td>5-Aug</td>
<td>5-Dec</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>---------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td><strong>R41, R42, R43, R44, U43, U44</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW</td>
<td>16-Feb</td>
<td>16-Jun</td>
<td>16-Oct</td>
</tr>
<tr>
<td>renewal, resubmission, revision</td>
<td>16-Mar</td>
<td>16-Jul</td>
<td>16-Nov</td>
</tr>
<tr>
<td><strong>K series</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW</td>
<td>12-Feb</td>
<td>12-Jun</td>
<td>12-Oct</td>
</tr>
<tr>
<td>renewal, resubmission, revision</td>
<td>12-Mar</td>
<td>12-Jul</td>
<td>12-Nov</td>
</tr>
<tr>
<td><strong>All AIDS and AIDS-Related</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Applications (for mechanisms cited above)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All - new, renewal, resubmission, revision</td>
<td>7-May</td>
<td>7-Sept</td>
<td>7-Jan</td>
</tr>
</tbody>
</table>

For the full schedule of NIH standard due dates, see [http://grants1.nih.gov/grants/funding/submissionschedule.htm](http://grants1.nih.gov/grants/funding/submissionschedule.htm)

**ABOUT THE BIRD:**

This compilation of general interest funding opportunities and announcements with possible collaborative potential is distributed to our pediatric research community monthly. It is compiled by the Emory-Children’s Pediatric Research Center to disseminate funding announcements of potential interest in a consolidated manner. More specific announcements are distributed in a more targeted fashion.

If you are not receiving this directly from Stacy Heilman and wish to be added to our Pediatric Research listserv, please e-mail [stacy.heilman@emory.edu](mailto:stacy.heilman@emory.edu) to make the request. Please also contact Stacy if you are interested in applying for any pediatric focused research funding opportunities and/or if you are interested in building collaborative efforts and programs towards applying for future pediatric research funding.